Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

University Hospital Freiburg1,500 enrolled

Overview

The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

HNSCC Oral Cavity Cancer Oropharynx Cancer Hypopharynx Cancer Larynx Cancer

Medical Language ↔ Plain English

Inclusion Criteria: * definitive (chemo-)radiotherapy of locoregionally advanced (cT3-4 and/or cN+) head-and-neck squamous cell carcinomas (HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx * primary treatment since 2005 * age ≥65 years at the time of (chemo-)radiotherapy Exclusion Criteria: * adjuvant (chemo-)radiotherapy * history of previous head-and-neck cancers or radiotherapy in the head-and-neck region * distant metastases at (chemo-)radiotherapy initiation (cM1) * HNSCCs of the nasopharynx, salivary glands, skin or with unknown primary

Locations (18)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine

Baltimore, Maryland, United States

COMPLETED

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai

New York, New York, United States

COMPLETED

Department of Radiation Oncology, Case Western Reserve University

Cleveland, Ohio, United States

COMPLETED

Division of Radiation Oncology, The Ohio State University Wexner

Columbus, Ohio, United States

COMPLETED

Radiation Oncology Department, German Oncology Center

Limassol, Cyprus

COMPLETED

Brno University Hospital

Brno, Czechia

COMPLETED

Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin

Berlin, Germany

COMPLETED

Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg

Erlangen, Germany

COMPLETED

Department of Radiotherapy and Oncology, Goethe-University Frankfurt am Main

Frankfurt, Germany

COMPLETED

University of Giessen

Giessen, Germany

COMPLETED

...and 8 more locations

Outcomes

Primary Outcomes

Overall survival (OS)

Time from radiotherapy start until death from any cause

Time frame: Up to 5 years

Secondary Outcomes

Progression-free survival (PFS)

Time from radiotherapy start until death from any cause, local progression, locoregional progression or distant progression (whichever occurs first)

Time frame: Up to 5 years

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Overview

Conditions

Eligibility

Locations (18)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts